Q1 EPS Estimates for Haemonetics Raised by Zacks Research

Haemonetics Corporation (NYSE:HAE) – Research analysts at Zacks Research lifted their Q1 2027 EPS estimates for shares of Haemonetics in a report released on Wednesday, January 28th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings of $1.20 per share for the quarter, up from their prior forecast of $1.19. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ FY2028 earnings at $5.90 EPS.

Other analysts have also recently issued research reports about the company. Citigroup lowered their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, October 7th. Barrington Research raised their target price on shares of Haemonetics from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Monday, January 12th. Robert W. Baird lifted their target price on shares of Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Finally, BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, January 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Haemonetics has a consensus rating of “Moderate Buy” and a consensus target price of $84.40.

Haemonetics Stock Up 0.9%

Shares of NYSE HAE opened at $66.54 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The company has a market cap of $3.11 billion, a P/E ratio of 19.46, a P/E/G ratio of 1.37 and a beta of 0.29. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32. The business has a 50-day simple moving average of $78.47 and a two-hundred day simple moving average of $65.50.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. The business had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.Haemonetics’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Hedge Funds Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in the business. New York State Teachers Retirement System lifted its stake in Haemonetics by 12.1% in the fourth quarter. New York State Teachers Retirement System now owns 55,888 shares of the medical instruments supplier’s stock worth $4,479,000 after acquiring an additional 6,043 shares during the period. Jennison Associates LLC raised its holdings in Haemonetics by 11.9% in the 4th quarter. Jennison Associates LLC now owns 12,103 shares of the medical instruments supplier’s stock worth $970,000 after purchasing an additional 1,290 shares in the last quarter. Cardinal Capital Management lifted its position in shares of Haemonetics by 1.5% in the 4th quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock worth $1,799,000 after purchasing an additional 321 shares during the period. M&T Bank Corp lifted its position in shares of Haemonetics by 31.0% in the 4th quarter. M&T Bank Corp now owns 6,154 shares of the medical instruments supplier’s stock worth $494,000 after purchasing an additional 1,457 shares during the period. Finally, Peregrine Capital Management LLC bought a new stake in shares of Haemonetics during the 4th quarter valued at about $2,293,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.